Using Minocycline to Treat Ulcerative Colitis
Clinical Study to Evaluate the Possible Efficacy and Safety of Minocycline in Patients With Ulcerative Colitis Treated With Mesalamine
This study is testing if adding Minocycline to the usual treatment can help people with mild to moderate Ulcerative Colitis feel better and reduce inflammation.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 46 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Mansoura) |
| Trial ID | NCT06201793 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Minocycline as an additional therapy for patients with mild to moderate Ulcerative Colitis (UC) who are already being treated with Mesalazine. The study aims to evaluate how Minocycline can help reduce inflammation and improve symptoms by targeting specific inflammatory pathways involved in UC. Participants will be monitored for changes in their condition and any potential side effects from the treatment. The trial is designed to provide insights into alternative treatment options for patients who may not respond adequately to standard therapies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with mild to moderate Ulcerative Colitis who are currently being treated with Mesalazine.
Not a fit: Patients with severe Ulcerative Colitis, those with significant liver or kidney issues, or individuals on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a new, effective option for managing Ulcerative Colitis, particularly for patients who do not respond to existing therapies.
How similar studies have performed: While some studies have explored the use of antibiotics in treating inflammatory bowel diseases, the specific application of Minocycline in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine) Exclusion Criteria: Patients with severe UC Pregnancy and lactating females Significant liver and kidney function abnormalities Diabetic patients Patients with Colorectal cancer patients Patients taking rectal or systemic steroids Patients on immunosuppressants or biological therapies Patients taking antacids, anticoagulants, bactericidal antibiotics, oral contraceptives, and isotretinoin. Addiction to alcohol and / or drugs Known allergy to the studied medications History of complete or partial colectomy.
Where this trial is running
Mansoura
- Faculty of Medicine, Mansoura University — Mansoura, Egypt (Recruiting)
Study contacts
- Study coordinator: Mostafa Bahaa
- Email: mbahaa@horus.edu.eg
- Phone: +201025538337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.